Overview Dividends

(HOWL) Werewolf Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95075A1079

Immunotherapy, Oncology, Solid Tumors, Lymphoma, Autoimmune

Risk via 10d forecast
Volatility 114%
Value at Risk 5%th 157%
Relative Tail Risk -16.24%
Reward TTM
Sharpe Ratio -0.54
Alpha -82.13
Character TTM
Hurst Exponent 0.649
Beta 2.118
Beta Downside 2.394
Drawdowns 3y
Max DD 92.04%
Mean DD 52.71%
Median DD 52.33%

Description: HOWL Werewolf Therapeutics October 19, 2025

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a U.S. biotech focused on engineering “INDUKINE” cytokine therapeutics that are conditionally activated to boost both adaptive and innate immunity, aiming to overcome the toxicity and efficacy limits of traditional pro-inflammatory cancer immunotherapies.

The firm’s flagship pipeline includes WTX-124 (a conditionally activated IL-2) and WTX-330 (a conditionally activated IL-12), both targeted at advanced or metastatic solid tumors, with additional candidates such as JZP898 (IFN-α), WTX-921 (IL-10 for inflammatory bowel disease), WTX-712 (IL-21) and WTX-518 (IL-18) in pre-clinical or early IND stages.

Key quantitative signals as of the most recent 10-Q (Q2 2024) show roughly $48 million in cash and short-term investments, providing an estimated 12-month runway at current burn rates; the company raised $30 million in a February 2024 private placement at a $300 million post-money valuation, indicating investor confidence despite the high-risk, early-stage profile. The broader immuno-oncology market is projected to grow at a CAGR of ~13 % through 2030, driven by expanding indications for cytokine-based therapies and increasing payer acceptance of targeted immune modulators.

For a deeper, data-driven view of HOWL’s valuation dynamics and risk-adjusted upside, you may find the analyst tools on ValueRay worth exploring.

HOWL Stock Overview

Market Cap in USD 56m
Sub-Industry Biotechnology
IPO / Inception 2021-04-30
Return 12m vs S&P 500 -58.5%
Analyst Rating 4.67 of 5

HOWL Dividends

Currently no dividends paid

HOWL Growth Ratios

CAGR 3y -21.42%
CAGR/Max DD Calmar Ratio -0.23
CAGR/Mean DD Pain Ratio -0.41
Current Volume 725.9k
Average Volume 678.8k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-72.8m TTM) > 0 and > 6% of Revenue (6% = 113.1k TTM)
FCFTA -0.80 (>2.0%) and ΔFCFTA -46.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 2683 % (prev 3300 %; Δ -617.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.80 (>3.0%) and CFO -63.5m > Net Income -72.8m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (45.8m) change vs 12m ago 4.80% (target <= -2.0% for YES)
Gross Margin 32.41% (prev 46.67%; Δ -14.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 1.72% (prev 2.45%; Δ -0.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -15.28 (EBITDA TTM -66.7m / Interest Expense TTM 4.47m) >= 6 (WARN >= 3)

Altman Z'' -28.94

(A) 0.64 = (Total Current Assets 68.2m - Total Current Liabilities 17.6m) / Total Assets 79.6m
(B) -5.87 = Retained Earnings (Balance) -467.0m / Total Assets 79.6m
warn (B) unusual magnitude: -5.87 — check mapping/units
(C) -0.62 = EBIT TTM -68.4m / Avg Total Assets 109.8m
(D) -9.34 = Book Value of Equity -467.0m / Total Liabilities 50.0m
Total Rating: -28.94 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 25.24

1. Piotroski 0.50pt = -4.50
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 1.26 = 1.76
5. Debt/Ebitda 0.43 = 2.36
6. ROIC - WACC (= -73.14)% = -12.50
7. RoE -144.4% = -2.50
8. Rev. Trend -93.17% = -6.99
9. EPS Trend -47.79% = -2.39

What is the price of HOWL shares?

As of November 15, 2025, the stock is trading at USD 0.92 with a total of 725,883 shares traded.
Over the past week, the price has changed by -20.16%, over one month by -45.02%, over three months by -30.44% and over the past year by -52.42%.

Is Werewolf Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Werewolf Therapeutics (NASDAQ:HOWL) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 25.24 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HOWL is around 0.71 USD . This means that HOWL is currently overvalued and has a potential downside of -22.83%.

Is HOWL a buy, sell or hold?

Werewolf Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy HOWL.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the HOWL price?

Issuer Target Up/Down from current
Wallstreet Target Price 6.8 642.4%
Analysts Target Price 6.8 642.4%
ValueRay Target Price 0.8 -14.1%

HOWL Fundamental Data Overview November 11, 2025

Market Cap USD = 55.8m (55.8m USD * 1.0 USD.USD)
P/S = 52.2151
P/B = 2.1175
Beta = 0.727
Revenue TTM = 1.89m USD
EBIT TTM = -68.4m USD
EBITDA TTM = -66.7m USD
Long Term Debt = 26.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 7.50m USD (from shortTermDebt, last quarter)
Debt = 37.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.4m USD (from netDebt column, last quarter)
Enterprise Value = 27.4m USD (55.8m + Debt 37.3m - CCE 65.7m)
Interest Coverage Ratio = -15.28 (Ebit TTM -68.4m / Interest Expense TTM 4.47m)
FCF Yield = -232.2% (FCF TTM -63.6m / Enterprise Value 27.4m)
FCF Margin = -3376 % (FCF TTM -63.6m / Revenue TTM 1.89m)
Net Margin = -3864 % (Net Income TTM -72.8m / Revenue TTM 1.89m)
Gross Margin = 32.41% ((Revenue TTM 1.89m - Cost of Revenue TTM 1.27m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.34 (Enterprise Value 27.4m / Total Assets 79.6m)
Interest Expense / Debt = 1.73% (Interest Expense 644.0k / Debt 37.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -54.0m (EBIT -68.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.87 (Total Current Assets 68.2m / Total Current Liabilities 17.6m)
Debt / Equity = 1.26 (Debt 37.3m / totalStockholderEquity, last quarter 29.6m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -28.4m / EBITDA -66.7m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -28.4m / FCF TTM -63.6m)
Total Stockholder Equity = 50.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -91.48% (Net Income -72.8m / Total Assets 79.6m)
RoE = -144.4% (Net Income TTM -72.8m / Total Stockholder Equity 50.4m)
RoCE = -89.32% (EBIT -68.4m / Capital Employed (Equity 50.4m + L.T.Debt 26.1m))
RoIC = -64.31% (negative operating profit) (NOPAT -54.0m / Invested Capital 84.0m)
WACC = 8.83% (E(55.8m)/V(93.1m) * Re(13.82%) + D(37.3m)/V(93.1m) * Rd(1.73%) * (1-Tc(0.21)))
Discount Rate = 13.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.91%
Fair Price DCF = unknown (Cash Flow -63.6m)
EPS Correlation: -47.79 | EPS CAGR: 9.28% | SUE: 0.36 | # QB: 0
Revenue Correlation: -93.17 | Revenue CAGR: -78.30% | SUE: 0.0 | # QB: 0

Additional Sources for HOWL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle